Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086489 · ClinicalTrials.gov registry record · Phase 2
CP-675,206 In Patients With Advanced Melanoma
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT00086489 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 118 participants.
The verdict
NCT00086489, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma
Interventions
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2003-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086489
The ClinicalTrials.gov registry entry for NCT00086489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-675,206 is the first listed.
NCT00086489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086489 about?
NCT00086489 is a clinical study titled "CP-675,206 In Patients With Advanced Melanoma". The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma
What is the current status of trial NCT00086489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2003-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00086489?
The interventions under investigation include: CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00086489?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.